ViiV adds to case for two-drug HIV regimen

24 July 2018
2019_biotech_test_vial_discovery_big

In its attempts to show the effectiveness of using two drug combinations in HIV, ViiV Healthcare has added more data to its evidence base.

The company, which is majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), has presented findings from the Phase III GEMINI 1 and 2 studies at the International AIDS conference in Amsterdam.

This data assessed the safety and efficacy of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine, in treatment-naïve, HIV-1 infected adults with baseline viral loads up to 500,000 copies per millilitre.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology